A social poll by the healthy living and aging platform, Goldster, revealed that over 65s are more open to trying microdosing than those under the age...
Algernon Pharmaceuticals has announced that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous formulation...
Psychedelics are being touted as a potential breakthrough in the area of mental health treatment.
Reunion Neuroscience has completed the interim data analysis for its Phase 1 clinical trial with lead asset RE104, a unique 4-OH-DiPT prodrug.
The first patient has been dosed in Small Pharma’s Phase I study that is comparing the profiles of the company’s proprietary formulation of DMT.
A global ayahuasca survey has found 70% experience physical and 55% mental health adverse effects, but only 2.3% of participants reporting physical adverse events required medical...
Tryp has announced interim data for the first five patients dosed in its Phase 2 trial, stating the data supports the potential effectiveness of psilocybin-assisted psychotherapy...
The nonprofit Multidisciplinary Association for Psychedelic Studies’ (MAPS) has announced its clinical research programme has had a successful confirmatory Phase 3 trial of MDMA-assisted therapy for...
Tryp Therapeutics and MGH will fund and conduct a Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients suffering from...
A new study, led by University of California – Riverside (UCR) doctoral ethnomusicology student Owain J.